Xu Cong Claire, Senior Vice President of Clinical Development at NovaBridge Biosciences (NASDAQ:NBP), executed a sale of 4,485 ordinary shares on July 6, 2026. The transaction resulted in proceeds of $3,991, with each share sold at a price of $0.89. These ordinary shares are represented by American Depositary Shares (ADSs), and the reported sales price reflects a converted ADS price of $2.04. The sale comes as NBP shares trade at $2.02, down roughly 50% over the past six months. According to InvestingPro analysis, the stock appears undervalued at current levels, with 8 additional ProTips available to subscribers analyzing the company’s financial health and prospects.
Prior to the sale, on July 4, 2026, Ms. Claire acquired 12,432 ordinary shares through the exercise of restricted share units (RSUs). Each RSU represents a contingent right to receive one ADS, and these RSUs were fully vested. The acquired ordinary shares are represented by 5,405 ADSs. Following these transactions, Ms. Claire directly holds 298,101 ordinary shares of NovaBridge Biosciences, which are represented by 129,609 ADSs. The Form 4 filing was submitted to the Securities and Exchange Commission on July 7, 2026.
In other recent news, NovaBridge Biosciences announced that the U.S. Food and Drug Administration granted Fast Track Designation for its drug givastomig. This designation applies to the combination of givastomig with nivolumab and chemotherapy for treating patients with specific types of advanced or metastatic gastroesophageal adenocarcinomas. The company’s Phase 1b data indicated both efficacy and tolerability for this treatment. Additionally, NovaBridge appointed Mark Hagler as President and Chief Commercial Officer. Hagler has over 25 years of experience in the pharmaceutical industry, previously leading a significant portfolio at Sun Pharmaceuticals Industries Limited. In terms of analyst perspectives, H.C. Wainwright reiterated a Buy rating for NovaBridge, citing the potential of the company’s VIS-101 drug candidate, which showed promising results in Phase 2a studies for wet age-related macular degeneration. These developments reflect ongoing progress and strategic changes within NovaBridge Biosciences.